Phase I first-in-human study of the polo-like kinase-1 selective inhibitor, GSK461364, in patients with advanced solid tumors
David Olmos(Spanish National Cancer Research Centre), Sarah P. Blagden(Churchill Hospital), Rohini Sharma(Hammersmith Hospital), André T. Brunetto(Queen's University Belfast), Douglas S. Barker(Queen's University Belfast), Anne B. Taegtmeyer(Queen's University Belfast), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Alicia J. Allred(Queen's University Belfast), Sharon C. Murray(BioCryst Pharmaceuticals (United States)), Deborah A. Smith(Research Triangle Park Foundation)
Cited by 22
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k